Use of circular RNA detection reagents and circular RNA inhibitors
By using the hsa_circ_0008623 circular RNA detection reagent and inhibitor, the challenges of early diagnosis and treatment of OSCC have been solved, achieving efficient early diagnosis and significant treatment effects, and providing a new molecular targeted therapy approach.
Patent Information
- Application Number
- CN202610409214.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-03-31
- Publication Date
- 2026-07-03
AI Technical Summary
The lack of highly specific and sensitive early diagnostic biomarkers in existing technologies makes it difficult to accurately identify patients with oral squamous cell carcinoma (OSCC) in the early stages, and the lack of effective molecular targeted therapy targets leads to poor treatment outcomes.
A circular RNA detection reagent using hsa_circ_0008623 as a diagnostic marker was used for early diagnosis by detecting its expression level, and small interfering RNA and small molecule inhibitors that target and inhibit hsa_circ_0008623 expression were used for treatment.
It enables early and accurate diagnosis and effective treatment of oral squamous cell carcinoma, significantly inhibits cancer cell proliferation, promotes apoptosis, and provides a new molecular targeted therapy approach.
Smart Images

Figure CN122326745A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of biotechnology, and more specifically, to the application of circular RNA detection reagents and circular RNA inhibitors. Background Technology
[0002] Oral squamous cell carcinoma (OSCC) is a malignant tumor that occurs in the squamous epithelium of the oral cavity. It is one of the most common head and neck malignant tumors worldwide, and my country is also one of the countries with a high incidence of this disease. In recent years, the number of new cases and deaths from oral squamous cell carcinoma in my country has remained high each year, placing a heavy medical burden on society and patients' families.
[0003] OSCC is highly invasive and metastatic, and its onset is insidious. Early symptoms are often atypical and easily confused with common oral ulcers or inflammation. In addition, most patients lack awareness of early screening, resulting in more than 60% of OSCC patients being diagnosed at an intermediate or advanced stage. Although some progress has been made in recent years in the comprehensive treatment of intermediate and advanced OSCC patients through surgical resection, radiotherapy, chemotherapy and other methods, the prognosis is still extremely poor. OSCC is very prone to local recurrence and cervical lymph node metastasis, resulting in the current overall 5-year survival rate of oral squamous cell carcinoma patients not exceeding 20%.
[0004] The extremely high late-stage diagnosis rate and extremely low survival rate of OSCC highlight the significant limitations of current clinical diagnostic and treatment methods: First, there is still a severe lack of highly specific and sensitive early diagnostic biomarkers, resulting in most patients not being accurately identified in the early stages of the disease, thus missing the optimal opportunity for early intervention; second, the pathogenesis of OSCC is extremely complex, and the lack of effective specific molecular intervention targets severely limits the application of existing molecular targeted therapies in OSCC. Therefore, in-depth exploration of the key molecular mechanisms in the development and progression of oral squamous cell carcinoma, actively seeking and identifying novel molecular biomarkers for accurate early diagnosis, and new therapeutic targets that can effectively block malignant tumor progression are of great significance for OSCC research. Summary of the Invention
[0005] The purpose of this invention is to provide a highly efficient diagnostic reagent and treatment product for oral squamous cell carcinoma.
[0006] To achieve the above objectives, the first aspect of the present invention provides the application of a circular RNA detection reagent in the preparation of oral squamous cell carcinoma diagnostic products, wherein the circular RNA detection reagent is an hsa_circ_0008623 detection reagent, wherein the nucleotide sequence of hsa_circ_0008623 is shown in SEQ ID No. 1.
[0007] A second aspect of the present invention provides a diagnostic product for oral squamous cell carcinoma, the oral squamous cell carcinoma diagnostic product comprising the circular RNA detection reagent as described in claim 1.
[0008] A third aspect of the present invention provides the use of a circular RNA inhibitor in the preparation of a therapeutic drug for oral squamous cell carcinoma, wherein the circular RNA inhibitor comprises small interfering RNA and / or small molecule hsa_circ_0008623 expression inhibitor that target and inhibit the expression of hsa_circ_0008623.
[0009] Preferably, the small interfering RNA that targets and inhibits the expression of hsa_circ_0008623 includes si-circRNA-0008623#1, which is composed of the nucleotide sequences shown in SEQ ID No. 2 and SEQ ID No. 3.
[0010] Preferably, the small interfering RNA that targets and inhibits the expression of hsa_circ_0008623 includes si-circRNA-0008623#2, which is composed of the nucleotide sequences shown in SEQ ID No. 4 and SEQ ID No. 5.
[0011] Compared with the prior art, the present invention has the following beneficial effects: 1. This invention is the first to discover that the expression level of hsa_circ_0008623 is closely related to the occurrence of oral squamous cell carcinoma. Based on this, hsa_circ_0008623 can be used as one of the diagnostic markers for oral squamous cell carcinoma. Detecting the expression level of hsa_circ_0008623 can be used as an effective means for early auxiliary diagnosis and prognostic assessment of oral squamous cell carcinoma. 2. This invention is the first to demonstrate that reducing the expression level of hsa_circ_0008623 can significantly inhibit the proliferation of oral squamous cell carcinoma cells and promote their apoptosis, and reveals the mechanism of action of hsa_circ_0008623 in oral squamous cell carcinoma, confirming that it has a significant positive correlation with AKT2 and IGF1R. This provides new ideas and new targets for the development of targeted drugs for oral squamous cell carcinoma. Attached Figure Description
[0012] Figure 1 This is the result of detecting the relative expression level of hsa_circ_0008623 in cancerous tissue and adjacent normal tissue in Example 1 of the present invention; Figure 2 The results of MTT analysis in Embodiment 2 of the present invention; Figure 3 These are the experimental results of the colony formation experiment in Embodiment 2 of the present invention; Figure 4 The results are experimental findings of apoptosis in Example 2 of this invention. Detailed Implementation
[0013] To make the above-mentioned objects, features, and advantages of the present invention more apparent and understandable, specific embodiments of the present invention are described in detail below. It should be noted that the following embodiments are only used to illustrate the implementation methods and typical parameters of the present invention, and are not intended to limit the parameter range described in the present invention. Reasonable variations derived therefrom are still within the protection scope of the present invention.
[0014] It should be noted that the endpoints and any values of the ranges disclosed herein are not limited to the precise ranges or values, and these ranges or values should be understood to include values close to these ranges or values. For numerical ranges, the endpoint values of the various ranges, the endpoint values of the various ranges and individual point values, and individual point values can be combined with each other to obtain one or more new numerical ranges, which should be considered as specifically disclosed herein.
[0015] As described in the background section, currently, there is a lack of effective diagnostic and therapeutic targets for oral squamous cell carcinoma in clinical practice. In view of this, the present invention provides an application of a circular RNA detection reagent and a circular RNA inhibitor.
[0016] Specifically, this invention provides the application of a circular RNA detection reagent in the preparation of oral squamous cell carcinoma diagnostic products. The circular RNA detection reagent is an hsa_circ_0008623 detection reagent, wherein the nucleotide sequence of hsa_circ_0008623 is shown in SEQ ID No. 1.
[0017] More specifically, SEQ ID No. 1: GACACTGTCTCAGTGCATCGCCCAGGCTTCTACGCTGAACGGTTCCAGCGCTTCATGTGCAACACAGTATTTAAGAAGATTCCCTTGAAGCCTTCTCCTTCCAAAAAGTTTCGGTCTGGCTCATCTTTCTCGGCGAGCAGGCTCCAGTGGCAACTCCTGCATTACTTACCAGCCATCGG TCTCTGGGGAACACAAGGCACAAGTGACAACAAAGGCAGAAGTGGAGCCAGGCGTTCACCTTGGTCGTCCTGATGTTTTACCTCAGACTCCACCTTTGGAGGAAATCAGTGAGGGCTCGCCTATTCCTGACCCCAGTTTCTCACCTCTAGTTGGAGAGACTTTGCAAATGCTAACTACAAG.
[0018] Another embodiment of the present invention provides a diagnostic product for oral squamous cell carcinoma, the oral squamous cell carcinoma diagnostic product comprising the circular RNA detection reagent provided in the foregoing embodiments.
[0019] Specific embodiments of the present invention also provide the application of circular RNA inhibitors in the preparation of therapeutic drugs for oral squamous cell carcinoma, wherein the circular RNA inhibitors include small interfering RNAs and / or small molecule hsa_circ_0008623 expression inhibitors that target and inhibit hsa_circ_0008623 expression.
[0020] In the above embodiments, the small interfering RNA that targets and inhibits the expression of hsa_circ_0008623 includes si-circRNA-0008623#1, which is composed of the nucleotide sequences shown in SEQ ID No. 2 and SEQ ID No. 3. More specifically, SEQ ID No.2: GCCUCAAUGGAGGUAGAAGAU; SEQ ID No. 3: AUCUUCUACCUCAUUGAGGCU.
[0021] In the above embodiments, the small interfering RNA that targets and inhibits the expression of hsa_circ_0008623 includes si-circRNA-0008623#2, which is composed of the nucleotide sequences shown in SEQ ID No. 4 and SEQ ID No. 5. More specifically, SEQ ID No.4: CAAUGGAGGUAGAAGAUGGCA; SEQ ID No. 5: UGCCAUCUUCUACCUCAUUGC.
[0022] The technical solutions of the present invention are further described below through specific embodiments. Unless otherwise defined, all terms, symbols, and other scientific terms used herein are intended to have the same meaning as commonly understood by one of ordinary skill in the art. In some cases, terms with a conventional understanding are limited herein for clarification or ease of reference, and such limitations should not be construed as indicating a significant difference from the conventional understanding in the art. The technical methods described or referenced herein are generally well understood by those skilled in the art and have been adopted by conventional methods. Unless otherwise stated, the use of commercially available kits, reagents, and instruments shall be performed according to the manufacturer's instructions and parameters.
[0023] Example 1 Validation of hsa_circ_0008623 as a diagnostic marker for oral squamous cell carcinoma This study included 104 patients with oral squamous cell carcinoma. The expression of hsa_circ_0008623 in oral squamous cell carcinoma tissue and adjacent normal tissue was detected using qRT-PCR. The specific procedure is as follows: Total RNA was extracted from 104 patients with oral squamous cell carcinoma using the TRIzol method. Ribosomal RNA was first removed using DNase I, followed by linear RNA removal using RNase R, enriching circular RNA. Circular RNA was then reverse transcribed into cDNA using a reverse transcription kit. The cDNA was amplified by qRT-PCR using primers shown in SEQ ID No. 6 and SEQ ID No. 7. Upstream primer SEQ ID No. 6: AGACATGGTGATGGTGGTG; Downstream primer SEQ ID No. 7: GTTGGTGTTGTTGTTGCTGCT.
[0024] After amplification, the relative expression levels of hsa_circ_0008623 in adjacent and cancerous tissues were calculated, and the results are as follows: Figure 1 As shown.
[0025] Depend on Figure 1 It is evident that there are significant differences in the relative expression levels of hsa_circ_0008623 between cancerous tissue and adjacent tissue, demonstrating the potential of hsa_circ_0008623 as a diagnostic marker for oral squamous cell carcinoma.
[0026] Example 2 Validation of the therapeutic potential of hsa_circ_0008623 inhibitors Two small interfering RNAs targeting the back splicing site of hsa_circ_0008623 were constructed and named si-circRNA-0008623#1 and si-circRNA-0008623#2, respectively. si-circRNA-0008623#1 consists of the nucleotide sequences shown in SEQ ID No. 2 and SEQ ID No. 3, and si-circRNA-0008623#2 consists of the nucleotide sequences shown in SEQ ID No. 4 and SEQ ID No. 5.
[0027] SEQ ID No.2: GCCUCAAUGGAGGUAGAAGAU; SEQ ID No. 3: AUCUUCUACCUCAUUGAGGCU.
[0028] SEQ ID No.4: CAAUGGAGGUAGAAGAUGGCA; SEQ ID No. 5: UGCCAUCUUCUACCUCAUUGC.
[0029] In addition, a nonspecific sequence was constructed as a negative control (siNC), which consisted of the nucleotide sequences shown in SEQ ID No. 8 and SEQ ID No. 9. SEQ ID No.8:UUCUCCGAACGUGUCACGUTT; SEQ ID No. 9: ACGUGACACGUUCGGAGAATT.
[0030] In this embodiment, SSC15 and CAL-27 cell lines were used as experimental cell lines. siNC, si-circRNA-0008623#1, and si-circRNA-0008623#2 were transfected into these cell lines, respectively. MTT assays, colony formation assays, and apoptosis assays were then performed. The MTT analysis results are as follows: Figure 2 As shown, the results of the colony formation experiment are as follows: Figure 3 As shown, the results of the apoptosis experiment are as follows: Figure 4 As shown. By Figures 2-4The results show that si-circRNA-0008623#1 and si-circRNA-0008623#2 provided by the present invention can effectively inhibit the proliferation of oral squamous cell carcinoma and increase apoptosis of oral squamous cell carcinoma cells, which proves the potential of si-circRNA-0008623#1 and si-circRNA-0008623#2 as targeted drugs for oral squamous cell carcinoma.
[0031] While the disclosure is as stated above, its scope of protection is not limited thereto. Those skilled in the art can make various changes and modifications without departing from the spirit and scope of this disclosure, and all such changes and modifications will fall within the protection scope of this invention.
Claims
1. Use of a circular RNA detection reagent in the manufacture of a product for diagnosing oral squamous cell carcinoma, characterized in that, The circular RNA detection reagent is the hsa_circ_0008623 detection reagent, wherein the nucleotide sequence of hsa_circ_0008623 is shown in SEQ ID No.
1.
2. A diagnostic product for oral squamous cell carcinoma, characterized in that, The oral squamous cell carcinoma diagnostic product includes the circular RNA detection reagent as described in claim 1.
3. The application of circular RNA inhibitors in the preparation of therapeutic drugs for oral squamous cell carcinoma, characterized in that, The circular RNA inhibitors include small interfering RNAs and / or small molecule hsa_circ_0008623 expression inhibitors that target and inhibit hsa_circ_0008623 expression.
4. The application as described in claim 3, characterized in that, The small interfering RNA that targets and inhibits the expression of hsa_circ_0008623 includes si-circRNA-0008623#1, which is composed of the nucleotide sequences shown in SEQ ID No. 2 and SEQ ID No.
3.
5. The application as described in claim 3, characterized in that, The small interfering RNA that targets and inhibits the expression of hsa_circ_0008623 includes si-circRNA-0008623#2, which is composed of the nucleotide sequences shown in SEQ ID No. 4 and SEQ ID No. 5.
